Humacyte's ATEV Outperforms Standard of Care in Phase 3, sBLA Filing Planned
HUMA sits 21% above its 52-week low of $0.547 on light trading volume (0.4× avg).
Summary
Humacyte reported Q2 2026 results with Symvess sales rising to $0.4M from $0.1M a year ago, but the real news is the breakthrough Phase 3 V012 data: ATEV outperformed AV fistula in female dialysis patients, delivering 91 more catheter-free days and fewer infections. The company plans an sBLA filing in H2 2026, which could expand the label significantly. Separately, the FDA accepted an IND for CTEV in CABG, with a Phase 2a study starting Q3 2026 — a potential new market with no off-the-shelf alternatives in 40 years. The commercial team has been rebuilt with new leadership and refined pricing strategies to drive hospital adoption. This follows the June 2026 interim analysis announcement and the recent Nasdaq delisting notice; the positive clinical data and regulatory progress could shift sentiment despite the going concern risk.
At the time of this announcement, HUMA was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $191.4M. The 52-week trading range was $0.55 to $2.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.